BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6576
- TODAY'S CHANGE (%)-0.0389 (-5.5851%)
- Bid / Lots0.6553/ 15
- Ask / Lots0.6725/ 4
- Open / Previous Close0.7100 / 0.6965
- Day Range
- 52 Week Range
- Volume267,897
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 480 | 0.7 |
| 09:38 ET | 100 | 0.7389 |
| 09:43 ET | 6884 | 0.7005 |
| 09:45 ET | 19521 | 0.69 |
| 09:48 ET | 160 | 0.688 |
| 09:54 ET | 6863 | 0.685 |
| 09:56 ET | 600 | 0.68805 |
| 09:57 ET | 1827 | 0.685 |
| 09:59 ET | 1201 | 0.6911 |
| 10:06 ET | 18243 | 0.68 |
| 10:08 ET | 6061 | 0.68 |
| 10:12 ET | 150 | 0.688799 |
| 10:14 ET | 100 | 0.6889 |
| 10:15 ET | 5859 | 0.6797 |
| 10:17 ET | 4795 | 0.662932 |
| 10:19 ET | 2800 | 0.6617 |
| 10:21 ET | 6800 | 0.6666 |
| 10:26 ET | 2517 | 0.6701 |
| 10:28 ET | 4500 | 0.679 |
| 10:30 ET | 800 | 0.674549 |
| 10:39 ET | 297 | 0.6745 |
| 10:42 ET | 1100 | 0.6768 |
| 10:44 ET | 700 | 0.6746 |
| 10:46 ET | 2700 | 0.6747 |
| 10:51 ET | 148 | 0.679 |
| 10:53 ET | 799 | 0.6789 |
| 11:06 ET | 110 | 0.6747 |
| 11:08 ET | 1100 | 0.679 |
| 11:11 ET | 2075 | 0.6701 |
| 11:15 ET | 500 | 0.674551 |
| 11:26 ET | 100 | 0.6768 |
| 11:27 ET | 2200 | 0.6783 |
| 11:29 ET | 1500 | 0.689 |
| 11:36 ET | 500 | 0.68455 |
| 11:38 ET | 5700 | 0.6801 |
| 11:40 ET | 13100 | 0.67 |
| 11:45 ET | 200 | 0.67505 |
| 11:51 ET | 1600 | 0.6701 |
| 12:00 ET | 6800 | 0.67 |
| 12:03 ET | 167 | 0.6801 |
| 12:12 ET | 149 | 0.67 |
| 12:16 ET | 600 | 0.6701 |
| 12:23 ET | 190 | 0.6801 |
| 12:30 ET | 100 | 0.6701 |
| 12:50 ET | 7950 | 0.67 |
| 12:52 ET | 225 | 0.677166 |
| 12:54 ET | 4000 | 0.6701 |
| 12:56 ET | 167 | 0.6795 |
| 12:59 ET | 300 | 0.671 |
| 01:08 ET | 200 | 0.6752 |
| 01:12 ET | 100 | 0.671 |
| 01:19 ET | 100 | 0.6793 |
| 01:21 ET | 100 | 0.671 |
| 01:28 ET | 330 | 0.67295 |
| 01:33 ET | 1794 | 0.67295 |
| 01:37 ET | 355 | 0.671039 |
| 01:39 ET | 295 | 0.674861 |
| 01:44 ET | 23544 | 0.67089 |
| 01:46 ET | 2775 | 0.6705 |
| 01:51 ET | 226 | 0.6708 |
| 01:55 ET | 2702 | 0.663 |
| 02:00 ET | 7300 | 0.6615 |
| 02:11 ET | 7250 | 0.655 |
| 02:13 ET | 1500 | 0.6551 |
| 02:22 ET | 1807 | 0.6552 |
| 02:38 ET | 1340 | 0.6579 |
| 02:44 ET | 1000 | 0.6605 |
| 02:49 ET | 100 | 0.6575 |
| 02:51 ET | 250 | 0.6579 |
| 02:56 ET | 3111 | 0.66 |
| 03:02 ET | 100 | 0.6579 |
| 03:03 ET | 106 | 0.66 |
| 03:05 ET | 100 | 0.65785 |
| 03:07 ET | 26900 | 0.6554 |
| 03:09 ET | 200 | 0.67 |
| 03:14 ET | 1000 | 0.665 |
| 03:18 ET | 350 | 0.67215 |
| 03:27 ET | 26050 | 0.6554 |
| 03:39 ET | 599 | 0.6554 |
| 03:43 ET | 200 | 0.6577 |
| 03:52 ET | 100 | 0.6577 |
| 03:57 ET | 600 | 0.659019 |
| 03:59 ET | 300 | 0.6576 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 60.1M | -0.9x | --- |
LAVA Therapeutics NV | 61.3M | -2.1x | --- |
Dyadic International Inc | 62.8M | -7.4x | --- |
Cue Biopharma Inc | 75.9M | -1.4x | --- |
Kezar Life Sciences Inc | 51.1M | -0.5x | --- |
BioXcel Therapeutics Inc | 61.2M | -0.3x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $60.1M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.56 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
